Carla M L Van Herpen
Overview
Explore the profile of Carla M L Van Herpen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
151
Citations
2980
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pal S, Loriot Y, Necchi A, Singh P, Castellano D, Pagliaro L, et al.
J Clin Oncol
. 2025 Feb;
:JCO2401675.
PMID: 39965176
Purpose: The COSMIC-021 study assessed the safety and efficacy of cabozantinib plus atezolizumab in advanced solid tumors. Presented here are results from the expansion cohorts with advanced urothelial carcinoma (UC)....
2.
van Ravensteijn S, Amir A, Tauriello D, Van Herpen C, Boers-Sonderen M, Wesseling Y, et al.
Clin Exp Immunol
. 2024 Dec;
219(1).
PMID: 39668127
Introduction: Immune checkpoint inhibition (ICI) is highly effective for the treatment of melanoma, but intrinsic resistance is present in a subgroup of patients. TGF-β pathway activity may play a role...
3.
de Heus E, Duijts S, van der Zwan J, Van Herpen C, Merkx M, Rutherford M, et al.
Cancer Epidemiol
. 2024 Nov;
94():102706.
PMID: 39579642
Background: As the survival proportions for rare cancers are on average worse than for common cancers, assessing the expected remaining life years in good health becomes highly relevant. This study...
4.
van Ruitenbeek N, Uijen M, Driessen C, Peters S, Prive B, van Engen-van Grunsven A, et al.
Theranostics
. 2024 Sep;
14(14):5388-5399.
PMID: 39310108
There is an urgent need for novel systemic therapies for recurrent/systemic salivary gland cancer, as current treatment options are scarce. [Ga]Ga-PSMA-11 PET/CT revealed relevant uptake of prostate-specific membrane antigen (PSMA)...
5.
Weijers J, Verhaegh G, Lassche G, van Engen-van Grunsven A, Driessen C, van Erp N, et al.
BMC Cancer
. 2024 Sep;
24(1):1174.
PMID: 39304797
Background: Salivary duct carcinoma (SDC) is a rare and aggressive subtype of salivary gland cancer, frequently associated with incurable recurrences and distant metastases (R/M). Proliferation of SDC relies on androgen...
6.
Zeverijn L, Geurts B, Battaglia T, van Berge Henegouwen J, de Wit G, Hoes L, et al.
Clin Cancer Res
. 2024 Jul;
30(19):4339-4351.
PMID: 39024037
Purpose: The treatment efficacy of nivolumab was evaluated in patients with advanced, treatment-refractory solid mismatch repair deficiency/microsatellite-instable (dMMR/MSI) tumors, and in-depth biomarker analyses were performed to inform precision immunotherapy approaches....
7.
Geurts B, Zeverijn L, Leek L, van Berge Henegouwen J, Hoes L, van der Wijngaart H, et al.
Clin Cancer Res
. 2024 Apr;
30(17):3735-3746.
PMID: 38630551
Purpose: To evaluate the efficacy of pembrolizumab across multiple cancer types harboring different levels of whole-genome sequencing-based tumor mutational load (TML; total of nonsynonymous mutations across the genome) in patients...
8.
Verkerk K, Geurts B, Zeverijn L, van der Noort V, Verheul H, Haanen J, et al.
Lancet Reg Health Eur
. 2024 Mar;
39:100875.
PMID: 38464480
Background: The DRUG Access Protocol provides patients with cancer access to registered anti-cancer drugs that are awaiting reimbursement in the Netherlands and simultaneously collects prospective real-world data (RWD). Here, we...
9.
Boers J, Eisses B, Zwager M, van Geel J, Bensch F, de Vries E, et al.
Diagnostics (Basel)
. 2024 Feb;
14(4).
PMID: 38396455
Background: In metastatic breast cancer (MBC), [F]fluorodeoxyglucose positron emission tomography/computed tomography ([F]FDG-PET/CT) can be used for staging. We evaluated the correlation between BC histopathological characteristics and [F]FDG uptake in corresponding...
10.
Weijers J, de Bitter T, Verhaegh G, van Boxtel W, Uijen M, van Engen-van Grunsven A, et al.
Oral Oncol
. 2023 Nov;
147:106620.
PMID: 37939426
No abstract available.